12/09/2025 11:30
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will host a webinar to discuss the company’s commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD) from 10:00-11:30 am ET on January 7, 2026. The discussion will include KOL and industry leaders’ perspectives on the current treatment lands...

11/12/2025 13:29
De' Longhi S.p.A. - Another Record Quarter: Revenues at €877 Million, up 11.5% at Constant Currency, and Adjusted EBITDA Margin at 17.0%. Guidance Raised

Approved by the Board of Directors of De' Longhi S.p.A. the consolidated results for the nine months of 2025. In the nine months the Group achieved: revenues for € 2,461.4 million, up by 10.4% with respect to 2024 (11.7% at constant currency); an adjusted Ebitda of € 389.5 million, equal to 15.8% on revenues (vs. 15.1% last year); a net income pertaining to the Group equal to € 187.6 million (+8.0% with respect to last year); a positive net financial position equal to € 308.7 mill...

Subscribe to